Advertisement

Topics

Newron Announces 2016 Financial Results and Provides Outlook for 2017

07:00 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Board approves agenda for AGM on March 28, 2017 Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous...

Other Sources for this Article

Media
Newron
Stefan Weber, +39 02 6103 46 26
CEO
pr@newron.com
or
U.K./Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Switzerland
IRF Communications
Martin Meier-Pfister, +41 (0)43 244 81 40
or
Germany
MC Services AG
Anne Hennecke, +49 (02)211 5292 5222
or
U.S.
LaVoieHealthScience
Beth Kurth, +1 617 374 8800, Ext. 104
or
Investors and Analysts
Newron
Stefan Weber, +39 02 6103 46 30
CEO
ir@newron.com
or
U.K./Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Germany/Continental Europe
MC Services AG
Anne Hennecke, +49 211 5292 5222
or
U.S.
LaVoieHealthScience
Beth Kurth, +1 617 374 8800, Ext. 106

NEXT ARTICLE

More From BioPortfolio on "Newron Announces 2016 Financial Results and Provides Outlook for 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...